Companies › IRulya Therapeutics
1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular, Respiratory; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LAM-001 | – | Phase 2 | Pulmonary Hypertension Due to Lung Diseases and Hypoxia; Bronchiolitis Obliterans Syndrome | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06018766 | LAM-001 | Phase 2 | Bronchiolitis Obliterans Syndrome | Respiratory | Dec 2026 |
| NCT05798923 | LAM-001 | Phase 2 | Pulmonary Hypertension Due to Lung Diseases and Hypoxia | Cardiovascular | Mar 2028 |
Cash and short-term investments of $116m on 2026-06-30; operating cash outflow about $54m a year; runway about 26 months at that burn, to Aug 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Contineum Therapeutics aTyr Pharma Braveheart Bio Rein Therapeutics Incannex Healthcare
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.